Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy

INTRODUCTION: Immune checkpoint inhibitors (ICIs) produce a broad spectrum of immune-related adverse events (irAEs) affecting various organ systems. While ICIs are established as a therapeutic option in non-small cell lung cancer (NSCLC) treatment, most patients receiving ICI relapse. Additionally,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayer, Michael R., Mambetsariev, Isa, Lu, Kun-Han, Wong, Chi Wah, Duche, Ashley, Beuttler, Richard, Fricke, Jeremy, Pharoan, Rebecca, Arvanitis, Leonidas, Eftekhari, Zahra, Amini, Arya, Koczywas, Marianna, Massarelli, Erminia, Roosan, Moom Rahman, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968834/
https://www.ncbi.nlm.nih.gov/pubmed/36860308
http://dx.doi.org/10.3389/fonc.2023.1064169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968834/
https://www.ncbi.nlm.nih.gov/pubmed/36860308
http://dx.doi.org/10.3389/fonc.2023.1064169

Ejemplares similares